AudioCure has made exciting progress in its preclinical program by extending both its indication and compound pipelines in recent months. We are very pleased to announce that we have therefore extended our scientific team to continue pushing our preclinical development forward.

“I am delighted to welcome our new colleagues to AudioCure” said CSO Hans Rommelspacher. “As well as being an excellent fit to the current team, they bring with them extensive expertise in both in vitro and in vivo research fields. This is an area in which AudioCure continues to make tremendous progress in developing novel compounds for the treatment of hearing disorders with an unmet medical need.”

With its most advanced compound AC102, AudioCure is about to enter the clinic with a focus on acute sensorineural hearing loss.

Continue reading on our Technology page.